Related Experiment Video
Updated: Sep 18, 2025
Author Spotlight: An Optimized Automated Method for Investigating Retinoic Acid Receptors in Neuronal Mitochondria
Published on: July 28, 2023
Subcellular redistribution of Rhein from whole cellular to single mitochondria for enhancing anti-hepatoma efficacy
Ling-Ling Wu1, Weihua Di1, Litao Shao2
1School of Pharmaceutical Sciences, National Key Laboratory of Advanced Drug Delivery System, Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong 250062, PR China.
Background:
RECQL4 is a critical factor in DNA repair and serves as a significant biomarker for liver cancer. Inhibiting RECQL4 induces apoptosis in liver cancer cells. Given the role of mitochondria in regulating apoptosis and the dual localization of RECQL4 in both the mitochondria and nucleus, targeting mitochondrial RECQL4 may induce mitochondrial dysfunction, thereby enhancing the therapeutic efficacy of liver cancer treatments.
Purpose:
Unlike traditional drug structure optimization, which focuses solely on protein target interactions, our approach optimizes drug structure based on both organelle distribution and protein interactions.
Methods:
As a proof of concept, we selected Rhein (4,5-dihydroxyanthraquinone-2-carboxylic acid), an auto-fluorescent, lipophilic anthraquinone found in a variety of different medicinal herbs used in TCM that is known to bind to RECQL4, a protein that is distributed throughout the cytosol, mitochondria, and other subcellular locations, albeit unevenly. Rhein has the tendency to accumulate in different subcellular organelles, which reduces the overall efficacy of the drug. To overcome this limitation, we conjugated a triphenylphosphonium group Rhein to direct the drug to the mitochondria, resulting in Rh-Mito.
Results:
Our results demonstrated that this chemical modification retains the ability to intervene in the expression of RECQL4 protein while also improving the cellular uptake of Rh-Mito. Utilizing advanced imaging techniques, we show that Rh-Mito preferentially accumulated in the mitochondria, where it targeted RECQL4 to inhibit the repair of mtDNA, altered the morphology of mitochondrial cristae, and induced apoptosis. Notably, Rh-Mito displayed superior anti-tumor efficacy compared to unmodified Rhein.
Conclusion:
Rh-Mito was designed to selectively target mitochondria, avoiding interactions with other organelles. This modification strengthens its binding to RECQL4, disrupts mitochondrial cristae, inhibits tumor cell migration, and promotes apoptosis, thereby improving its therapeutic efficacy in liver cancer treatment.
Insights
Targeting mitochondrial RECQL4 with Rh-Mito, a modified Rhein compound, enhances liver cancer treatment by inducing apoptosis and improving anti-tumor efficacy. This approach optimizes drug delivery for greater therapeutic impact.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Therapeutics
Background:
- RECQL4 is crucial for DNA repair and a biomarker in liver cancer.
- Inhibiting RECQL4 induces apoptosis in liver cancer cells.
- Mitochondria regulate apoptosis; targeting mitochondrial RECQL4 may enhance cancer therapy.
Purpose of the Study:
- To optimize drug structure based on both organelle distribution and protein interactions, moving beyond traditional target-focused approaches.
- To develop a novel therapeutic strategy for liver cancer by targeting mitochondrial RECQL4.
Main Methods:
- Selected Rhein, a known RECQL4 binder, and conjugated it with a triphenylphosphonium group to create Rh-Mito for mitochondrial targeting.
- Investigated the effects of Rh-Mito on RECQL4 expression, cellular uptake, mitochondrial function, and apoptosis in liver cancer cells.
Main Results:
- Rh-Mito demonstrated enhanced cellular uptake and preferential accumulation in mitochondria.
- Mitochondrial targeting of RECQL4 by Rh-Mito inhibited mtDNA repair and altered mitochondrial morphology.
- Rh-Mito induced apoptosis and showed superior anti-tumor efficacy compared to unmodified Rhein.
Conclusions:
- Rh-Mito selectively targets mitochondria, enhancing binding to RECQL4 and disrupting mitochondrial function.
- This targeted approach promotes apoptosis and inhibits tumor cell migration, improving therapeutic efficacy for liver cancer.
- Rh-Mito represents a promising strategy for enhancing liver cancer treatment through targeted mitochondrial intervention.
Related Concept Videos
01:46Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
01:19Translocation of Proteins into the Mitochondria
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...